Resultados de la búsqueda 31-40 of 14914 for Tyrosine

  1. Hematología - Ensayos clínicos - Mayo Clinic

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  2. Hematología - Ensayos clínicos

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®). Cardio-Oncology ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) ... The Standard of Care options are: an EGFR tyrosine kinase inhibitor ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...